{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:36:08Z","timestamp":1790868968725,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.jtct.2023.12.010","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T20:18:20Z","timestamp":1702930700000},"page":"283.e1-283.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1673-9670","authenticated-orcid":false,"given":"Othman S.","family":"Akhtar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3351-8829","authenticated-orcid":false,"given":"Karnav","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongphil","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Skelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5164-9163","authenticated-orcid":false,"given":"Mohammed A.","family":"Al-Jumayli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Extermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"De Avila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0423-5870","authenticated-orcid":false,"given":"Omar","family":"Castaneda Puglianini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Grajales Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Blue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Shain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Alsina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9945-4381","authenticated-orcid":false,"given":"Hien","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0662-6480","authenticated-orcid":false,"given":"Ciara L.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2023.12.010_bib0001","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.12.010_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2023.12.010_bib0003","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.jtct.2023.12.010_bib0004","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.12.010_bib0005","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.12.010_bib0006","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2023.12.010_bib0007","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-21-2031","article-title":"Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy","volume":"27","author":"Zhang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.12.010_bib0008","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s00384-006-0259-6","article-title":"Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer","volume":"22","author":"McMillan","year":"2007","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.jtct.2023.12.010_bib0009","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/j.ejca.2011.03.028","article-title":"A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study","volume":"47","author":"Proctor","year":"2011","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jtct.2023.12.010_bib0010","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s11605-010-1162-6","article-title":"Comparison of pre-treatment clinical prognostic factors in patients with gastro-oesophageal cancer and proposal of a new staging system","volume":"14","author":"Crumley","year":"2010","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.jtct.2023.12.010_bib0011","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/pcan.2011.60","article-title":"Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study","volume":"15","author":"Shafique","year":"2012","journal-title":"Prostate Cancer Prostat Dis"},{"key":"10.1016\/j.jtct.2023.12.010_bib0012","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.lungcan.2020.11.026","article-title":"Clinical utility of pretreatment Glasgow prognostic score in non-small-cell lung cancer patients treated with immune checkpoint inhibitors","volume":"152","author":"Takamori","year":"2021","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtct.2023.12.010_bib0013","article-title":"Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors","volume":"9","author":"Jacqueline","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"10.1016\/j.jtct.2023.12.010_bib0014","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.4049\/jimmunol.1402909","article-title":"C-Reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis","volume":"194","author":"Zhang","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.jtct.2023.12.010_bib0015","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2023.12.010_bib0016","doi-asserted-by":"crossref","first-page":"12778","DOI":"10.1182\/blood-2022-158080","article-title":"Baseline systemic inflammatory markers interleukin 6 and ferritin are associated with toxicities and progression-free survival in multiple myeloma patients treated with idecabtagene vicleucel","volume":"140","author":"Hansen","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.12.010_bib0017","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Kai","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2023.12.010_bib0018","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2021-150431","article-title":"A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.12.010_bib0019","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2023.12.010_bib0020","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.12.010_bib0021","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2023.12.010_bib0022","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","article-title":"Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"39","author":"Martin","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jtct.2023.12.010_bib0023","doi-asserted-by":"crossref","first-page":"7506","DOI":"10.1182\/blood-2022-165266","article-title":"The CAR-hematotox score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"140","author":"Rejeski","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2023.12.010_bib0024","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/eji.200635207","article-title":"C-reactive protein impairs human CD14+ monocyte-derived dendritic cell differentiation, maturation and function","volume":"36","author":"Zhang","year":"2006","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.jtct.2023.12.010_bib0025","article-title":"C reactive protein impairs adaptive immunity in immune cells of patients with melanoma","volume":"8","author":"Tatsuya","year":"2020","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.jtct.2023.12.010_bib0026","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1056\/NEJM199902113400607","article-title":"Acute-phase proteins and other systemic responses to inflammation","volume":"340","author":"Gabay","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2023.12.010_bib0027","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/hep.27644","article-title":"Prostaglandin E2-mediated immunosuppression and the role of albumin as its modulator","volume":"61","author":"Choe","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jtct.2023.12.010_bib0028","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/nm.3516","article-title":"Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2","volume":"20","author":"O\u2019Brien","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2023.12.010_bib0029","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ajcn\/82.3.531","article-title":"Lower serum albumin concentration and change in muscle mass: the Health, Aging and Body Composition Study","volume":"82","author":"Visser","year":"2005","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.jtct.2023.12.010_bib0030","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1182\/blood-2021-149784","article-title":"Sarcopenia Is a clinically relevant and independent predictor of health outcomes after chimeric antigen receptor T-Cell Therapy for Lymphoma","volume":"138","author":"Iukuridze","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2023.12.010_bib0031","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-22-0487","article-title":"Influence of adipose tissue distribution, sarcopenia, and nutritional status on clinical outcomes after CD19 CAR T-cell therapy","volume":"11","author":"Rejeski","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.jtct.2023.12.010_bib0032","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1182\/blood-2022-168071","article-title":"Sarcopenia prevalence and influence on the development of toxicity and length of stay in patients with relapsed and refractory myeloma treated with commercial anti-BCMA CART cells","volume":"140","author":"Parker","year":"2022","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723017451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636723017451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:13:26Z","timestamp":1763003606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636723017451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2666636723017451"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2023.12.010","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simple Score of Albumin and CRP Predicts High-Grade Toxicity in Patients with Multiple Myeloma Receiving CAR-T Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2023.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}